Comparative Pharmacology
Head-to-head clinical analysis: ATARAX versus CLARITIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATARAX versus CLARITIN.
ATARAX vs CLARITIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydroxyzine is a piperazine derivative with antihistaminic (H1-receptor antagonist) and anticholinergic properties; also exhibits sedative, anxiolytic, and antiemetic effects due to suppression of activity in subcortical areas of the CNS.
Loratadine is a long-acting tricyclic antihistamine with selective peripheral H1 receptor antagonistic activity. It inhibits histamine release from mast cells and reduces allergic responses.
25 mg orally 3-4 times daily; maximum 100 mg per day. Also available as 50 mg intramuscular injection every 4-6 hours.
10 mg orally once daily for adults and children ≥6 years.
None Documented
None Documented
Terminal elimination half-life is approximately 20-25 hours in healthy adults; may be prolonged in elderly, hepatic impairment, or renal insufficiency (up to 30-40 hours); steady-state achieved within 3-4 days.
Terminal elimination half-life 27 hours (range 22-30 hours); clinical context: allows once-daily dosing, steady state reached in 5-7 days
Primarily hepatic metabolism via CYP3A4 and CYP2D6; renal excretion of metabolites accounts for approximately 70-80% of the dose, with less than 1% excreted unchanged; fecal excretion is about 10-15%.
Renal 40% as metabolites, fecal 40% as metabolites, biliary <5% as unchanged drug
Category C
Category C
Antihistamine
Antihistamine